Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 6/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672984 | 0.83 | PTGS2 (0.50) | NPC1RAB9AKMT2AHTR2A | |
| SCHEMBL2763268 | 0.81 | NPC1 (0.43) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL2923177 | 0.80 | MGLL (0.56) | NPC1RAB9AMEN1KMT2ACYP2D6 | |
| SCHEMBL2763299 | 0.79 | SRC (0.48) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL2762912 | 0.78 | NPC1 (0.41) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL3750287 | 0.77 | NPC1 (0.49) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL14312085 | 0.77 | SRD5A2 (0.54) | SRD5A2KMT2AHTR2A | |
| SCHEMBL11195181 | 0.77 | SRD5A2 (0.54) | SRD5A2KMT2AHTR2A | |
| SCHEMBL14312084 | 0.77 | SRD5A2 (0.54) | SRD5A2KMT2AHTR2A | |
| SCHEMBL2762748 | 0.76 | KCNH2 (0.44) | NPC1RAB9ASRD5A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091938-B1 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTISUB II INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-6930197-B2 | Antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-6730791-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-05-04 | — | — | US | disclosed |
| US-6700012-B2 | FOR THERAPY OF ALLERGIC DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2004-03-02 | — | — | US | disclosed |
| US-6689898-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-02-10 | — | — | US | disclosed |
| US-6683094-B2 | 4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL)BUTYL) -ALPHA-(HYDROXYMETHYL)-ALPHA-METHYL-BENZENEACETIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. | 2004-01-27 | — | — | US | disclosed |
| US-6673933-B2 | 1-(3-(4-(1,1-BIS(ALKYOXYCARBONYL)ALKYL)PHENYL)CARBONYLPROPYL), 4-(HYDROXYDIPHENYLMETHYL)PIPERIDINE | AVENTIS PHARMACEUTICAL INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-08-15 | — | — | US | disclosed |
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH2, HRH1, HRH4 | NPC1 1460/4885RAB9A 3030/4885SRD5A2 3735/4885 |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | NPC1 895/4885RAB9A 2598/4885SRD5A2 2641/4885 |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | NPC1 708/4885RAB9A 1808/4885SRD5A2 1683/4885 |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | NPC1 860/4885RAB9A 1981/4885SRD5A2 2377/4885 |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | NPC1 976/4885RAB9A 2788/4885SRD5A2 2180/4885 |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | NPC1 830/4885RAB9A 2449/4885SRD5A2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.